危重症与创伤中的红细胞生成素。

Erythropoietin in Critical Illness and Trauma.

机构信息

Western Health, Footscray Hospital, Gordon Street Footscray, Melbourne, VIC 3011, Australia; The University of Melbourne, Parkville, VIC 3010, Australia; Monash University, School of Public Health and Preventive Medicine, 553 St Kilda Road, Melbourne, VIC 3004, Australia.

出版信息

Crit Care Clin. 2019 Apr;35(2):277-287. doi: 10.1016/j.ccc.2018.11.015. Epub 2019 Jan 28.

DOI:10.1016/j.ccc.2018.11.015

PMID:30784609

Abstract

Erythropoietin (EPO) is a 34kD pleiotropic cytokine that was first identified as being essential for red blood cell (RBC) production. It is now recognized however that EPO is produced by many tissues. It plays a key role in the modulation of the response to injury, inflammation, and tissue hypoxia via the inhibition of apoptosis. Large clinical trials in the critically ill failed to demonstrate a role for EPO as an RBC transfusion sparing agent; however, improved clinical outcomes, attributable to EPO role in tissue protection are observed in critically ill trauma patients. Further research to confirm or refute these observations is required.

摘要

促红细胞生成素（EPO）是一种 34kD 的多效细胞因子，最初被确定为红细胞（RBC）生成所必需。然而，现在人们已经认识到，EPO 是由许多组织产生的。它通过抑制细胞凋亡在调节对损伤、炎症和组织缺氧的反应中发挥关键作用。在危重病患者中进行的大型临床试验未能证明 EPO 作为红细胞输血节约剂的作用；然而，在危重病创伤患者中观察到 EPO 在组织保护中的作用导致了临床结局的改善。需要进一步的研究来证实或反驳这些观察结果。